The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Marketwire

Merus Labs International Inc. Announces Promotion & Distribution Agreements for Emselex(R)/Enablex(R) in Canada & Slovenia

Tuesday, February 19, 2013

Merus Labs International Inc. Announces Promotion & Distribution Agreements for Emselex(R)/Enablex(R) in Canada & Slovenia16:12 EST Tuesday, February 19, 2013TORONTO, ONTARIO--(Marketwire - Feb. 19, 2013) -Merus Labs International Inc. ("Merus" or the "Company") (TSX:MSL)(NASDAQ:MSLI) is pleased to announce that through its wholly owned subsidiaries, Merus Labs Netherlands B.V and Merus Labs Luxco S.à R.L., it has entered into promotion and distribution agreements with partners in Canada and Slovenia for the Company's Emselex®/Enablex® product. Emselex®/Enablex® (darifenacin) is a branded prescription medicine in extended release tablet form which is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. The partner companies and corresponding territories are as follows; NorrizonRx Sales and Marketing Group Inc. (Canada) and Proksimum Pharma d.o.o. (Slovenia). Under the terms of the agreements, the partner companies have been granted exclusive rights to market and sell Emselex®/Enablex® in their respective territories. The financial terms of the agreements have not been disclosed. For the year 2012, the newly partnered territories had net sales of approximately US$4.5 million. About Merus Labs International Inc. Merus is a specialty pharmaceutical company engaged in the acquisition and licensing of pharmaceutical products. The Company utilizes its expertise in pharmaceutical markets and its access to capital to acquire and license niche branded products. Merus further enhances the sale and distribution of these products by the introduction of a focused marketing and promotion plan.Cautionary Statement Certain statements contained in this press release may constitute "forward-looking statements" within the meaning of Section 21E (i) (1) of the United States Securities Exchange Act of 1934. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Merus' actual results to be materially different from any future results expressed or implied by these statements. Such factors include the following: general economic and business conditions, changes in demand for Merus' products, changes in competition, the ability of Merus to integrate acquisitions or complete future acquisitions, interest rate fluctuations, currency exchange rate fluctuations, dependence upon and availability of qualified personnel and changes in government regulation. In light of these and other uncertainties, the forward-looking statements included in this press release should not be regarded as a representation by Merus that Merus' plans and objectives will be achieved. These forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise the statements.FOR FURTHER INFORMATION PLEASE CONTACT: Contact Information: Merus Labs International Inc.Elie FarahPresident and CEO(416) 593-3701efarah@meruslabs.com